"NANOBIOTIX Partners for Global Development and Commercialization of Groundbreaking Radioenhancer NBTXR3"

Nanobiotix has announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica for the investigational radioenhancer NBTXR3, which is being evaluated in several studies for the treatment of solid tumors. Under the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3, with Nanobiotix receiving near-term cash and operational support valued up to $60 million. Nanobiotix will maintain operational control of ongoing studies and NBTXR3 manufacture, while Janssen will be responsible for an initial Phase 2 study for lung cancer. Nanobiotix is eligible for success-based payments of up to $1.8 billion, as well as royalties on net sales of NBTXR3.